Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.51 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448634 | 0.95 | PPARA (0.52) | PPARAPPARG | |
| SCHEMBL29209337 | 0.87 | PPARA (0.52) | PPARAPPARGGGPS1PLK1 | |
| SCHEMBL29648269 | 0.87 | PLK1 (0.57) | PPARAPPARGGGPS1PLK1 | |
| SCHEMBL16541074 | 0.85 | PPARA (0.44) | PPARAPPARG | |
| SCHEMBL30599779 | 0.83 | PPARA (0.52) | PPARAPPARGGGPS1PLK1 | |
| SCHEMBL14330020 | 0.83 | PLK1 (0.53) | PPARAPPARGPLK1 | |
| SCHEMBL15049836 | 0.83 | PLK1 (0.62) | PPARAPPARGGGPS1PLK1 | |
| SCHEMBL3817643 | 0.82 | SOD1 (0.46) | — | |
| SCHEMBL1791490 | 0.82 | MAPK1 (0.45) | — | |
| SCHEMBL29790833 | 0.82 | SOD1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2249426-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEM CORP (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-10320030-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-11 | — | — | US | disclosed |
| US-9083058-B2 | Nonaqueous electrolytic solution and nonaqueous-electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-07-14 | — | — | US | disclosed |
| US-20150140448-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2869389-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | Mitsubishi Chemical Corporation (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-8916298-B2 | Nonaqueous electrolytic solution and nonaqueous-electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-12-23 | — | — | US | disclosed |
| US-8889302-B2 | Nonaqueous electrolytic solution and nonaqueous-electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-11-18 | — | — | US | disclosed |
| US-8846254-B2 | — | — | 2014-09-30 | — | — | US | disclosed |
| US-20140134481-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-05-15 | — | — | US | disclosed |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20120308883-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120219854-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20110123871-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY | MITSUBISHI CHEMCIAL (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2249426-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | Mitsubishi Chemical Corporation (JP) | 2010-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | PPARA 174/4885PPARG 688/4885GGPS1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.